Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. - Test2 - elhamkhani - TriplyDB

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

http://www.wikidata.org/entity/Q35209900

about

Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies Pediatric AML: From Biology to Clinical Management How I treat pediatric acute myeloid leukemia Childhood acute myeloid leukaemia Prognosis and management of acute myeloid leukemia in patients with Down syndrome Advancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cure Measurable residual disease testing in acute myeloid leukaemia.Current Management of Childhood Acute Myeloid Leukemia.Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.Joint analysis of longitudinal data and recurrent episodes data with application to medical cost analysis.CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.Regression analysis of longitudinal data with informative observation times and application to medical cost data.Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.Minimal residual disease in acute myeloid leukaemia Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Definition of cure in childhood acute myeloid leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.Recent advancements of flow cytometry: new applications in hematology and oncology.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.Novel agents for the treatment of childhood acute leukemia.Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCT Challenging issues in pediatric oncology Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.Association between CEBPE Variant and Childhood Acute Leukemia Risk: Evidence from a Meta-Analysis of 22 Studies.

P2860

Q26770394-4E16D871-954C-4795-857F-22D8CE834E92 Q26799773-B9DC7282-699E-45C5-9F52-5538AC10DD6C Q26992280-71C1B8B2-B2E8-40F5-A997-58CB6EAC0A7F Q27005960-D7B5F936-976A-4228-8F28-1C24A3F38C90 Q27016577-8A81982F-84A6-4D49-A239-3BAE7F248C33 Q27027799-388EEDB2-7D41-4839-8F29-21FB8D86B541 Q30234914-AA80DECD-B44D-42CD-A69C-640522337C31 Q30244036-987FDB74-1FC1-4B3D-8D7A-E2A4BA7EC39E Q30244244-6FAFF11C-59C6-45A7-B741-24E941550037 Q30580885-516A8F3A-3254-49BB-9DDD-9E36D92820F6 Q31138226-B6749389-EF19-4FE1-A819-0757A6A1E7BB Q33573539-D4142224-2F22-4517-8EE3-E3711BB5290B Q33779342-44825C82-D133-4795-B12E-44F891F082CB Q33826582-C031A5C5-D676-496D-B74D-61AA2B40EDD6 Q33852603-5C2ECA4C-F054-47BB-A596-4FC7BDFDA53F Q33875554-CCD45881-829E-41AA-A559-ABFC76D868C4 Q34021009-A8BFC531-9B2C-4368-B92B-E2C1300992A4 Q34179265-B4BF47EC-9EF1-41F0-97CC-B6E351FCF15F Q34193514-3125AA67-4026-46B3-91E8-536402B60AE5 Q34380489-ED5DBFC2-5F36-44AE-AF9C-761C26C77DA6 Q34544769-3775C8F3-64DE-4A56-8FC9-D7241AF819F6 Q34674124-2833029A-00BF-4CE6-BE3C-12C07540F14F Q34742630-8834AE60-B4A9-446D-AD1A-D625AAD9917E Q34747454-35B79B22-29E4-47C8-B1E8-D21B9CC217EB Q34764504-969A7918-5FF1-4A18-AE26-88E8BB6FAEDA Q34809196-1A415061-866D-4159-93B8-29AFD33440EA Q35007971-9CABB471-5F4E-4AAA-B833-D9A9F33BDB61 Q35031403-95B15D50-A045-455B-A2FA-00AEF52D4423 Q35048344-411F9A4A-AB48-4563-8A56-F18A28A06B6C Q35059549-E3179C7E-5BFE-4222-8BCF-74740FBFDC6D Q35112199-44781647-62D2-4929-B127-77CB74818235 Q35114704-2BD5F95A-93FC-4FAD-9D35-987082490CD9 Q35172210-1D59862C-00D8-4A8A-96AE-3E25654526C1 Q35186322-B0405CF9-76DA-4521-BC28-1E7865F15A11 Q35192790-FA1E9092-D5E5-46AE-90B9-DC27F2E1BC15 Q35265653-A8AE6BAB-5F01-4DFA-A114-52F4CC2FA3D4 Q35582360-B0917654-036B-4E39-AFB1-2DD2F654F595 Q35602419-6C198A82-1F9F-4202-A4BE-8CE80BEA481F Q35615051-4A07C2FE-F433-413A-8370-928FD0894220 Q35621513-8039D4E5-8644-47CB-950D-B2B2E4029F3D

P2860

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

http://www.wikidata.org/entity/Q35209900

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@ast

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@en

type

label

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@ast

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@en

prefLabel

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@ast

Minimal residual disease-direc ...... f the AML02 multicentre trial.

@en

P1433

Q35209900-70ECBC14-686C-4685-8CE7-DCBFBAC1DF0A

P1476

Q35209900-615650CF-F977-4B12-90C4-C6D9DD455E8B

P2093

Q35209900-12561B90-6F9B-4C1F-B37C-51924C4C199C

Q35209900-169C6742-952B-497C-A970-392CEEDE342D

Q35209900-17D8AD88-FFFD-4AC1-B0FD-C21871502807

Q35209900-56B740E0-1CF1-46A7-BA62-01C45D2867F5

Q35209900-5C10D461-8A48-4F42-97F4-8DA8025431EE

Q35209900-6A9A24FD-2E2B-4761-891D-3102AEAF59BB

Q35209900-737946C8-0163-4F6F-B435-6644FEAB4D02

Q35209900-7564F428-C720-483D-820D-CCFAB48835E6

Q35209900-8A5105AE-A850-4777-ACAA-C2206D811ED7

Q35209900-B36AAA30-6206-406A-BFC7-F93AF59C5E60

P2860

Q35209900-0568D728-791E-4CA4-A8CB-EDFCA36CD7C4

Q35209900-0B3E2645-1C8A-444B-9E67-734FCF698754

Q35209900-2BE15F1B-EBB0-4E44-A93B-7F89F7C1F672

Q35209900-3A8E5D5E-87D6-4094-8487-1CBE3EB7784D

Q35209900-40CAD396-BE86-44E4-A1C0-01E9E53B1FD4

Q35209900-4684761B-AA25-4745-9A5A-188C1742FF6F

Q35209900-57CA533C-9847-4C1E-893D-DC17E2671B21

Q35209900-5A478D53-5E35-435A-B024-F3B6913F485F

Q35209900-6184A3D9-9CC6-4C97-BDD4-4ABE9FA6ABF2

Q35209900-6F976844-D788-4BE8-A638-4FE4A5CDC1E4

P304

Q35209900-ADDAEADE-012B-4EAF-915D-7B67FDB2D078

P31

Q35209900-515BE73C-182D-46CA-90B9-69081925E090

P356

Q35209900-E5657B36-CE6F-4B0D-B1EE-EC5A3190EBCF

P433

Q35209900-B30501BF-29FC-4339-9A4C-2D5B34926259

P478

Q35209900-6E81F98F-8736-4256-B751-88EE2526E851

P50

Q35209900-3EDB5BDB-CAEE-4999-B4E3-D2646781EECD

Q35209900-7AB32A50-EC58-4C16-94E1-FFB499D89DBF

P577

Q35209900-5D9F6EEA-FADB-489A-A59E-990DAD7624D2

P5875

Q35209900-F3C2539D-C9AB-4ECB-9D60-7C0C527F8698

P698

Q35209900-635A1EA9-4920-4846-918B-0F42EBBF6D65

P921

Q35209900-8C00A5F0-A142-4165-84F3-9017933C781F

Q35209900-D540ACE9-9EAF-4CE0-8BE3-EB20A714FA76

P932

Q35209900-324FC4E7-40AD-400C-84CE-4F9F5A4C840A

P356

S1470-2045(10)70090-5

P1433

The Lancet Oncology

P1476

Minimal residual disease-direc ...... of the AML02 multicentre trial

@en

P2093

Barbara Degar

http://www.w3.org/2001/XMLSchema#string

Bassem I Razzouk

http://www.w3.org/2001/XMLSchema#string

Ching-Hon Pui

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Elaine Coustan-Smith

http://www.w3.org/2001/XMLSchema#string

Gary Dahl

http://www.w3.org/2001/XMLSchema#string

Gladstone Airewele

http://www.w3.org/2001/XMLSchema#string

Hiroto Inaba

http://www.w3.org/2001/XMLSchema#string

James R Downing

http://www.w3.org/2001/XMLSchema#string

Jeffrey Taub

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Treating childhood acute lymphoblastic leukemia without cranial irradiation

A multiple testing procedure for clinical trials

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Favorable impact of the t(9;11) in childhood acute myeloid leukemia.

P304

543-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(10)70090-5

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Rubnitz

P577

2010-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44581569

http://www.w3.org/2001/XMLSchema#string

P698

20451454

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3171799

http://www.w3.org/2001/XMLSchema#string